Lung function in men with and without HIV
- PMID: 32287070
- PMCID: PMC7362901
- DOI: 10.1097/QAD.0000000000002526
Lung function in men with and without HIV
Abstract
Objectives: Initial studies suggest HIV-positive persons may be at increased risk for chronic lung diseases such as chronic obstructive pulmonary disease, but have commonly relied on single-center designs, lacked HIV-negative controls, or assessed lung function with only spirometry. We tested differences in spirometry and single-breath diffusing capacity for carbon monoxide (DLCO) in persons with and without HIV.
Design: Cross-sectional, observational study.
Methods: Participants were enrolled from the Multicenter AIDS Cohort Study, a longitudinal cohort study of men who have sex with men (both HIV-positive and HIV-negative) at four sites in the United States. Standardized spirometry and DLCO testing were performed in all eligible, consenting participants at routine study visits. We tested associations between HIV status and spirometry and DLCO results, using linear and logistic regression.
Results: Among 1067 men, median age was 57 years, prevalence of current marijuana (30%), and cigarette (24%) use was high, and another 45% were former cigarette smokers. Median forced expiratory volume in 1 s was 97% of predicted normal and DLCO was 85% of predicted normal. HIV-positive persons demonstrated no statistical difference in forced expiratory volume in 1 s compared with HIV-negative persons, but had worse DLCO (adjusted difference -2.6% of predicted; 95% confidence interval: -4.7 to -0.6%) and a higher risk of DLCO impairment (odds ratio for DLCO < 60% of predicted 2.97; 95% confidence interval: 1.36-6.47). Lower DLCO was associated with lower nadir CD4 cell counts.
Conclusion: HIV-positive men are at increased risk of abnormal gas exchange, indicated by low DLCO, compared with men without HIV.
Conflict of interest statement
Conflicts of interest
All authors have received grant support from NIH for the work presented here. K.M.K. has received consultancy fees from GlaxoSmithKline and Nuvaira, Inc. outside the work presented here; has received contracted clinical trial support from AstraZeneca and Sanofi outside the work presented here. R.J. has received consultancy fees from ndd Medical Technologies. D.C., G.D., M.E.F., V.S., and A.M.: nothing to declare. M.C.M. has received consultancy fees from GlaxoSmithKline and royalties from UpToDate outside the work presented here.
Figures
References
-
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:1859–1922. - PMC - PubMed
-
- Bigna JJ, Kenne AM, Asangbeh SL, Sibetcheu AT. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob Health 2018; 6:e193–e202. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL146245/HL/NHLBI NIH HHS/United States
- U01 HL146205/HL/NHLBI NIH HHS/United States
- U01 HL146208/HL/NHLBI NIH HHS/United States
- U01 HL146192/HL/NHLBI NIH HHS/United States
- U01 HL146242/HL/NHLBI NIH HHS/United States
- UM1 AI035043/AI/NIAID NIH HHS/United States
- U01 HL146201/HL/NHLBI NIH HHS/United States
- U01 HL146193/HL/NHLBI NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- U01 HL146194/HL/NHLBI NIH HHS/United States
- U01 HL146241/HL/NHLBI NIH HHS/United States
- P30 AI027767/AI/NIAID NIH HHS/United States
- P30 AI050409/AI/NIAID NIH HHS/United States
- U01 HL146333/HL/NHLBI NIH HHS/United States
- U01 HL146204/HL/NHLBI NIH HHS/United States
- U01 HL146202/HL/NHLBI NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 HL146240/HL/NHLBI NIH HHS/United States
- U01 HL146203/HL/NHLBI NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
